Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 11 October 2007. doi:10.1136/thx.2007.083592
Thorax 2008;63:228-233
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society.

LUNG CANCER

Autoantibodies in lung cancer: possibilities for early detection and subsequent cure

C J Chapman1, A Murray2, J E McElveen2, U Sahin3, U Luxemburger3, Ö Türeci3, R Wiewrodt3, A C Barnes2, J F Robertson1,2

1 Division of Breast Surgery, The University of Nottingham, Nottingham, UK
2 Oncimmune Ltd, Nottingham City Hospital, Nottingham, UK
3 Department of Medicine III, Johannes Gutenberg University, Mainz, Germany

Dr C J Chapman, Division of Breast Surgery, Clinical Sciences Building, Nottingham City Hospital, Nottingham NG5 1PB, UK; caroline.chapman{at}nottingham.ac.uk

Background: People with lung cancer usually present at a late stage in the course of their disease when their chances of long-term survival are low. At present there is little to offer for early diagnosis, even in those at high risk of developing the disease. Autoantibodies have been shown to be present in the circulation of people with various forms of solid tumour before cancer-associated antigens can be detected, and these molecules can be measured up to 5 years before symptomatic disease.

Objective: To assess the potential of a panel of tumour-associated autoantibody profiles as an aid to other lung cancer screening modalities.

Methods: Plasma from normal controls (n = 50), patients with non-small cell lung cancer (n = 82) and patients with small cell lung cancer (n = 22) were investigated for the presence of autoantibodies to p53, c-myc, HER2, NY-ESO-1, CAGE, MUC1 and GBU4-5 by enzyme-linked immunosorbent assay.

Results: Raised levels of autoantibodies were seen to at least 1/7 antigens in 76% of all the patients with lung cancer plasma tested, and 89% of node-negative patients, with a specificity of 92%. There was no significant difference between the detection rates in the lung cancer subgroups, although more patients with squamous cell carcinomas (92%) could be identified.

Conclusion: Measurement of an autoantibody response to one or more tumour-associated antigens in an optimised panel assay may provide a sensitive and specific blood test to aid the early detection of lung cancer.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Babel, I., Barderas, R., Diaz-Uriarte, R., Martinez-Torrecuadrada, J. L., Sanchez-Carbayo, M., Casal, J. I. (2009). Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays. Mol. Cell. Proteomics 8: 2382-2395 [Abstract] [Full Text]  
  • Mazzone, P. J (2009). Give me a sign, any sign. Thorax 64: 737-738 [Full Text]  
  • Desmetz, C., Bascoul-Mollevi, C., Rochaix, P., Lamy, P.-J., Kramar, A., Rouanet, P., Maudelonde, T., Mange, A., Solassol, J. (2009). Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women. Clin. Cancer Res. 15: 4733-4741 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Chest Medicine Jobs

Chest Medicine Jobs